In many life sciences sales, especially of earlier-stage companies, the buyer pays a modest amount at closing. The rest comes only if the asset succeeds, through development, regulatory and sales milestones, and sometimes through royalties on future sales. How much of the headline value is contingent varies widely. In the life sciences sales I have advised on, it has ranged from under half to more than 90 percent, measured as the share of upfront plus potential milestone payments that is payable…
By: Potomac Law Group, PLLC
By: Potomac Law Group, PLLC
